Advertisement
AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

AJPH First Look, published online ahead of print Sep 17, 2008
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
AJPH.2008.144584v1
98/11/1927    most recent
Right arrow Submit a response
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Get other permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldsworthy, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Goldsworthy, R.
Related Collections
Right arrow Other Health Financing
Right arrow Influenza
November 2008, Vol 98, No. 11 | American Journal of Public Health 1927
© 2008 American Public Health Association
DOI: 10.2105/AJPH.2008.144584

LETTERS

GOLDSWORTHY RESPONDS

Richard Goldsworthy, PhD

The author is with Academic Edge, Inc, Bloomington, IN.

Correspondence: Requests for reprints should be sent to Richard Goldsworthy, Academic Edge, Inc, 108 E 14th St, Bloomington, IN 47408 (e-mail: rick{at}academicedge.com).

Mitchell's letter concerning our study raises an important public health issue related to prescription medication sharing that our study—focused as it was on direct effects on consumers—did not consider: the impact of such sharing on research and evaluation predicated upon prescription data sources. Mitchell is absolutely correct in asserting that there is considerable potential for consumer loaning and borrowing of prescription medication to affect the accuracy of traditional adverse effects reporting systems. We agree that efforts using these sources, whether for ongoing surveillance or as part of clinical trials, may need to take into consideration the potential underreporting of adverse effects that may be present when prescription medications are shared.

Accepted for publication July 15, 2008.





This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
AJPH.2008.144584v1
98/11/1927    most recent
Right arrow Submit a response
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Get other permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldsworthy, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Goldsworthy, R.
Related Collections
Right arrow Other Health Financing
Right arrow Influenza

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Public Health Association